French biotech startup Generare has secured a €5 million Series A funding round led by venture capital firms Alven and Daphni. The funding will accelerate the development of its proprietary platform for producing human milk proteins, aiming to transform infant nutrition and therapeutic applications.

Generare, founded in 2021, leverages precision fermentation technology to manufacture complex proteins identical to those found in human breast milk. This approach addresses critical limitations of existing infant formulas, which rely on bovine milk proteins that are structurally different and can be difficult for some infants to digest. The company's initial focus is on producing lactoferrin and alpha-lactalbumin, key proteins with demonstrated benefits for immune function and nutrient absorption.

The investment round attracted participation from existing shareholders, including business angels and Bpifrance, via its Digital Venture fund. Generare plans to allocate the new capital toward expanding its R&D capabilities, scaling its bioproduction processes, and initiating regulatory engagement for its products.

Co-founders Romainville and Lebreton, who bring backgrounds in bioprocess engineering and business development from the biopharma sector, emphasize the platform's potential beyond infant nutrition. Their long-term vision includes applying these high-purity proteins to medical nutrition and specific therapeutic markets.

The investment underscores a growing VC interest in European biotech and food-tech alternatives. Alven and Daphni cite Generare's scientific approach, scalable technology, and addressable market as key factors in their decision to lead the round. The startup now joins a competitive landscape of companies using fermentation to create novel food ingredients, with a distinct focus on replicating the biological benefits of human milk.

L’article Alven et Daphni mènent la série A de la biotech Generare est apparu en premier sur Maddyness - Le média pour comprendre l'économie de demain.